Snider Financial Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
Other funds holding XBI
ACA
MCMC
CI
Snider Financial Group's XBI Position: Q1 2022 in Review
Snider Financial Group sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2022, closing a stake of 46,214 shares — an estimated $5.33M sold.
Snider Financial Group first reported a position in XBI in Q2 2021 and held it in 3 quarters. The position peaked at $5.53M in Q3 2021. 703 funds tracked by Wall St. Rank hold XBI as of Q1 2022.
- Snider Financial Group reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2022 after selling out during the quarter.
- Snider Financial Group sold 46,214 State Street SPDR S&P Biotech ETF shares in Q1 2022, an estimated $5.33M.
- Snider Financial Group first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and held it in 3 quarters.
- Snider Financial Group's State Street SPDR S&P Biotech ETF position peaked at $5.53M in Q3 2021.
- 703 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2022.
Based on Snider Financial Group's 13F filing for Q1 2022, filed 13 May 2022.